scholarly journals Central Nervous System Involvement in Burkitt’s Lymphoma

Blood ◽  
1970 ◽  
Vol 36 (6) ◽  
pp. 718-728 ◽  
Author(s):  
JOHN L. ZIEGLER ◽  
AVRUM Z. BLUMING ◽  
RICHARD H. MORROW ◽  
LEROY FASS ◽  
PAUL P. CARBONE
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Systemic Chemotherapy ◽  
Central Nervous System Involvement ◽  
Burkitt’S Lymphoma ◽  
Intrathecal Chemotherapy ◽  
Burkitt's Lymphoma ◽  
Cranial Neuropathy ◽  
Tumor Extension ◽  
System Involvement

Abstract Thirty-five of 77 patients (46%) with Burkitt’s lymphoma presented or developed evidence of central nervous system involvement by tumor. Neurologic abnormalities included paraplegia, cranial neuropathy, altered levels of consciousness and malignant pleocytosis. An analysis of this series disclosed the following: Paraplegia is a common presenting feature of Burkitt’s lymphoma and is responsive to systemic chemotherapy. The association of cranial neuropathy and malignant pleocytosis with facial tumors points to direct tumor extension to intracranial structures (duraarachnoid) as the pathogenesis of these lesions. Intrathecal chemotherapy temporarily reverses malignant pleocytosis but systemic chemotherapy is required to treat cranial neuropathy. A poor prognosis follows presentation or development of malignant pleocytosis. The limitations of the current forms of therapy for CNS involvement are discussed.

scholarly journals Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Nil Albiol ◽  
Silvana Novelli ◽  
Anna Mozos ◽  
Marta Pratcorona ◽  
Rodrigo Martino ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Central Nervous System Involvement ◽  
Intrathecal Chemotherapy ◽  
Infectious Complications ◽  
Haematopoietic Stem Cell ◽  
System Involvement ◽  
Cell Neoplasm

Abstract Background We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting. Case presentation A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow). He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient’s disease progressed and so he succumbed due to infectious complications. Conclusions Venetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.

scholarly journals Central Nervous System Involvement is Associated with Ibrutinib-Induced Severe Hyperleukocytosis and Controlled by the Combination of Intrathecal Chemotherapy in Chronic Lymphocytic Leukemia: A Case Report

2021 ◽  
Vol 6 (4) ◽  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chronic Lymphocytic Leukemia ◽  
Rare Complication ◽  
Combined Treatment ◽  
Central Nervous System Involvement ◽  
Intrathecal Chemotherapy ◽  
Lymphocytic Leukemia ◽  
System Involvement ◽  
Ighv Gene

Central nervous system involvement (CNSi) is a rare complication of chronic lymphocytic leukemia (CLL) with a very poor prognosis. Its diagnosis, predictive factors, and standard treatment remain elusive. Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase, has been approved to treat CLL, yet little is known of its effect on the occurrence and management of CNSi. Here, we report, for the first time, an elderly CLL patient with secondary CNSi following ibrutinib-induced severe hyperleukocytosis, characterized by subcutaneous lesions and unmutated IgHV gene. Ibrutinib combined with intrathecal chemotherapy induced a prompt and durable remission of CNSi. This case indicates that severe hyperleukocytosis caused by ibrutinib is associated with the emergence of CNSi, and a combined treatment with intrathecal chemotherapy is effective and safe in the treatment of CLL patient with CNSi.

Central nervous system involvement in American Burkitt's lymphoma.

1983 ◽  
Vol 1 (11) ◽  
pp. 677-681 ◽  
Author(s):  
E Sariban ◽  
B Edwards ◽  
C Janus ◽  
I Magrath
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
Burkitt’S Lymphoma ◽  
Cranial Irradiation ◽  
Burkitt's Lymphoma ◽  
Cns Involvement ◽  
Cns Disease ◽  
Cns Relapse

Sixty-four patients with American Burkitt's lymphoma (AMBL) treated at the National Cancer Institute were reviewed to determine the frequency and characteristics of central nervous system (CNS) involvement. Patients with minimal or completely resected tumor never had CNS disease. Of the 45 patients with more extensive disease, 15 had CNS disease: nine presented with CNS disease, six of whom subsequently had recurrent CNS disease, and six developed CNS disease only at relapse. There was a significant association between CNS and bone-marrow disease at presentation. Therapy of CNS disease consisted of short courses of intrathecal chemotherapy with cytosine arabinoside and methotrexate. Cranial irradiation was given only to patients with CNS relapse. There are six long-term survivors (LTS) who have been disease free for four to six years post chemotherapy. Of these six LTS, three presented with CNS disease, two experienced isolated CNS relapse, and one had CNS disease both at presentation and at relapse. Three of the six LTS never received cranial irradiation. It is concluded that CNS involvement in AMBL can be effectively treated, and that long-term remission, which is probably cure, can be achieved.

Central nervous system involvement in childhood brucellosis

2001 ◽  
Vol 21 (3) ◽  
pp. 291-292 ◽  
Author(s):  
Hüseyin Çaksen ◽  
Dursun Odabaş ◽  
Şükrü Arslan ◽  
Ahmet Faik Oner
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
System Involvement
Sign in / Sign up

Export Citation Format

Share Document